These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 31238507

  • 1. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS).
    El-Salhy M, Hausken T, Hatlebakk JG.
    Nutrients; 2019 Jun 24; 11(6):. PubMed ID: 31238507
    [Abstract] [Full Text] [Related]

  • 2. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome.
    El-Salhy M, Casen C, Valeur J, Hausken T, Hatlebakk JG.
    World J Gastroenterol; 2021 May 14; 27(18):2219-2237. PubMed ID: 34025075
    [Abstract] [Full Text] [Related]

  • 3. Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females.
    El-Salhy M, Gilja OH, Hatlebakk JG.
    Scand J Gastroenterol; 2024 Apr 14; 59(4):391-400. PubMed ID: 38084725
    [Abstract] [Full Text] [Related]

  • 4. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM.
    Gut; 2018 Dec 14; 67(12):2107-2115. PubMed ID: 29980607
    [Abstract] [Full Text] [Related]

  • 5. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila VJ, Tillonen J, Satokari R, Arkkila P.
    Aliment Pharmacol Ther; 2020 Jun 14; 51(12):1321-1331. PubMed ID: 32343000
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
    El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T.
    Gut; 2020 May 14; 69(5):859-867. PubMed ID: 31852769
    [Abstract] [Full Text] [Related]

  • 7. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation.
    Mazzawi T, Lied GA, Sangnes DA, El-Salhy M, Hov JR, Gilja OH, Hatlebakk JG, Hausken T.
    PLoS One; 2018 May 14; 13(11):e0194904. PubMed ID: 30427836
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms.
    El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG.
    Scand J Gastroenterol; 2022 Sep 14; 57(9):1036-1045. PubMed ID: 35486073
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation.
    El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG.
    Gastroenterology; 2022 Oct 14; 163(4):982-994.e14. PubMed ID: 35709830
    [Abstract] [Full Text] [Related]

  • 11. Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation.
    El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG.
    Neurogastroenterol Motil; 2022 Sep 14; 34(9):e14353. PubMed ID: 35302268
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome.
    El-Salhy M, Kristoffersen AB, Valeur J, Casen C, Hatlebakk JG, Gilja OH, Hausken T.
    Neurogastroenterol Motil; 2022 Jan 14; 34(1):e14200. PubMed ID: 34145677
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota.
    Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, Zhou YL, Yao F, Nie YQ, Zhou YJ.
    J Dig Dis; 2019 Aug 14; 20(8):401-408. PubMed ID: 31070838
    [Abstract] [Full Text] [Related]

  • 15. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, De Looze D.
    Gastroenterology; 2021 Jan 14; 160(1):145-157.e8. PubMed ID: 32681922
    [Abstract] [Full Text] [Related]

  • 16. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D.
    Singh P, Alm EJ, Kelley JM, Cheng V, Smith M, Kassam Z, Nee J, Iturrino J, Lembo A.
    Gut Microbes; 2022 Jan 14; 14(1):2020067. PubMed ID: 35014601
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, Gilja OH, Hatlebakk JG, Lied GA.
    Scand J Gastroenterol; 2019 Jun 14; 54(6):690-699. PubMed ID: 31190584
    [Abstract] [Full Text] [Related]

  • 19. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.
    Halkjær SI, Lo B, Cold F, Højer Christensen A, Holster S, König J, Brummer RJ, Aroniadis OC, Lahtinen P, Holvoet T, Gluud LL, Petersen AM.
    World J Gastroenterol; 2023 May 28; 29(20):3185-3202. PubMed ID: 37346153
    [Abstract] [Full Text] [Related]

  • 20. The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Mazzawi T, El-Salhy M, Lied GA, Hausken T.
    Front Cell Infect Microbiol; 2021 May 28; 11():524851. PubMed ID: 34055657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.